

This is a preprint - author's version of a work published as version of record in <http://dx.doi.org/10.1177/0271678X251361261>

Citation for final published version:

Maccioni, Lucia, Brusaferri, Ludovica, Barzon, Leonardo, Schubert, Julia J., Nettis, Maria A., Cousins, Oliver, Rosenzweig, Ivana, Mizuno, Yuya, Vicente-Rodriguez, Marta, Singh, Nisha, Marques, Tiago R., Harrison, Neil A. , Fryer, Tim, Bullmore, Edward T., Cash, Diana, Mondelli, Valeria, Pariante, Carmine, Howes, Oliver, Turkheimer, Federico E., Loggia, Marco L. and Veronese, Mattia 2025. A novel blood-free analytical framework for the quantification of neuroinflammatory load from TSPO PET imaging. *Journal of Cerebral Blood Flow & Metabolism* 45 (12) , pp. 2283-2300. 10.1177/0271678X251361261

A novel blood-free analytical framework for the quantification of neuroinflammatory load from TSPO PET Imaging

Lucia Maccioni¹, Ludovica Brusafferri^{2,3}, Leonardo Barzon¹, Julia J. Schubert⁴, Maria A. Nettis⁴, Oliver Cousins⁴, Ivana Rosenzweig⁴, Yuya Mizuno^{4,5,6}, Marta Vicente-Rodríguez^{4,7}, Nisha Singh⁴, Tiago Reis Marques^{4,8}, Neil A. Harrison⁹, Tim Fryer¹⁰, Edward T. Bullmore¹¹, Diana Cash⁴, Valeria Mondelli⁴, Carmine Pariante⁴, Oliver Howes^{4,12}, Federico E. Turkheimer⁴, Marco L. Loggia^{2,13}, Mattia Veronese^{1,4}

Affiliations

¹Department of Information Engineering, University of Padova, Padova, Italy

²Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA

³Computer Science and Informatics, School of Engineering, London South Bank University, London, UK

⁴Institute of Psychology, Psychiatry and Neuroscience, King's College London, London, UK

⁵South London and Maudsley NHS Foundation Trust, London, UK

⁶Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

⁷Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain

⁸Psychiatric Imaging Group, MRC London Institute of Medical Sciences (LMS), Hammersmith Hospital, Imperial College London, London, UK

⁹Cardiff University Brain Research Imaging Centre (CUBRIC), Cardiff University, Cardiff, UK

¹⁰Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, Cambridge, UK

¹¹Department of Psychiatry, School of Clinical Medicine, University of Cambridge, Cambridge, UK

¹²Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK

¹³Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA

Corresponding authors

Lucia Maccioni

Department of Information Engineering, University of Padova

Via Gradenigo 6/B, 35122, Padova, Italy

+39 049 827 7640

lucia.maccioni.1@phd.unipd.it

<https://orcid.org/0000-0002-6564-2827>

Mattia Veronese

Department of Information Engineering, University of Padova

Via Gradenigo 6/B, 35122, Padova, Italy

+39 049 827 7654

mattia.veronese@unipd.it

<https://orcid.org/0000-0003-3562-0683>

Running headline

Blood- and reference-free TSPO PET quantification

Abstract

Positron Emission Tomography (PET) of 18 kDa translocator protein (TSPO) has been investigated as putative marker of neuroinflammation but faces substantial methodological challenges. These include issues with arterial blood sampling for kinetic modeling, the absence of suitable reference regions, genetic polymorphisms affecting tracer affinity, altered blood-to-brain tracer delivery in inflammatory conditions, and high signal variability. This study presents a novel blood-free reference-free method for TSPO PET quantification, leveraging a logistic regression model to estimate the probability of TSPO overexpression across brain regions. Validation was performed on 323 human brain scans from five datasets and three radiotracers. The quantified TSPO topology in healthy controls showed strong concordance with constitutive TSPO gene expression for all tracers. When using [^{11}C]PBR28 PET data, the method replicated previous findings in schizophrenia, Alzheimer's disease, chronic pain, and XBD173 blocking. However, model extension to [^{18}F]DPA-714 and [^{11}C](R)-PK11195 revealed small effect sizes and high variability, suggesting the need for tracer-specific model optimization. Finally, validation in a rat model of lipopolysaccharide-induced neuroinflammation confirmed previous evidence of increased brain TSPO uptake after systemic challenge.

This novel non-invasive method provides individualized TSPO PET quantification, demonstrating broad applicability across TSPO PET tracers and imaging sites, assuming sufficient training data for model development.

Keywords: blood-free quantification, neuroinflammation, normative modeling, PET, TSPO

1. Introduction

Positron Emission Tomography (PET) imaging targeting the 18 kDa translocator protein (TSPO) has been widely investigated as a potential tool for the derivation of quantitative biomarkers of neuroinflammation^{1,2}. Clinical interest in TSPO arises from the fact that TSPO is upregulated by microglia, astrocytes, and macrophages during neuroinflammatory processes^{3–5}. Although TSPO lacks specificity for proinflammatory microglia^{5–8}, regional increases in TSPO PET signal have been associated with elevated densities of glial and immune cells^{7,9}, a hallmark of neuroinflammatory response. Despite many debates and concerns about its biological interpretability, TSPO PET imaging has been investigated as a putative biomarker of neuroinflammation across a wide spectrum of neurodegenerative, psychiatric, and inflammatory disorders, as well as chronic pain conditions^{8,10–14}. A recent meta-analysis identified more than 150 individual case-control studies, encompassing over five thousand scans of healthy controls and patients¹⁵.

However, quantification for this class of radioligand remains challenging. Standard blood-based kinetic modeling has practical and methodological problems^{16,17}, including the need for invasive catheterization for arterial blood sampling, the challenges of accurately measuring radioactivity in blood and plasma, and the need to correct for the radioactivity of tracer metabolites as well as for the plasma protein binding. The latter is particularly challenging, as the magnitude of TSPO radiotracers free plasma fraction is generally modest (<5%)^{10,18,19} and sensitive to the presence of inflammatory proteins^{20–22}. An alternative to blood-based modeling is the use of a reference region with perfusion and non-displaceable binding properties similar to the tissues of interest but minimal or no expression of the ligand's target^{23,24}. However, while TSPO expression in the brain is relatively low, it is ubiquitously expressed across most cell types²⁵, which significantly complicates reference-based quantification. Additionally, the normalization for the signal in the reference region might limit, in some cases, the ability to detect the brain-wide effects of a disease²⁶.

The large and often unpredictable intra- and inter-individual biological variability in the TSPO PET signal adds to this complexity. This variability hampers the statistical power to detect group effects linked to specific disorders and may have contributed to inconsistent evidence regarding the role of neuroinflammatory processes in both physiological conditions and various brain pathologies²⁷. One possible explanation for this variability might be related to the unclear

relationship between peripheral and central inflammation, as well as the role of blood-brain-barrier (BBB) alterations, which affect the rate of tracer delivery from blood to parenchyma and thus the measured activity of the tracer in the tissue^{22,28–30}. Another source of variability arises from human genetic differences in tracer affinity due to the single nucleotide polymorphism in the TSPO gene (rs6971)³¹, which affect the utility of the newer-generation TSPO radiotracers developed to address the limitations of [¹¹C]-(R)-PK11195, such as its high non-specific binding and low target affinity^{10,19}. Genotype analysis allows for the stratification of subjects into more homogeneous cohorts (high-affinity binders (HAB), mixed-affinity binders (MAB), and low-affinity binders (LAB)). However, for several tracers LABs must be excluded from the study due to the impossibility of providing a reliable signal, although third-generation radioligands like ER176 have sufficient sensitivity to image LABs. Other factors such as subjects' sex, age, and body mass index (BMI) have been shown to affect the baseline brain inflammatory load and, consequently, TSPO binding^{32–34}. Taken together, this evidence underscores the importance of understanding the physiological mechanisms underlying TSPO PET variability to enable more accurate quantification of individual neuroinflammatory status.

In this work, we propose a new non-invasive blood-free reference-free analytical framework for the quantification of dynamic TSPO PET imaging based on a logistic regression model. The use of a logistic function transforms the linear combination of a set of independent variables (*i.e.*, the model covariates/predictors) into a probability value between 0 and 1. Here, we defined a logistic regression model that takes brain TSPO PET raw time activity curves (TACs) as predictors to provide a probability measure of the tissue to manifest an overexpression of TSPO. The model is enriched with additional inputs, including the estimate of tracer perfusion and tracer blood-to-brain extraction, and a set of individual covariates representing possible confounders of interest for the brain TSPO signal.

Our approach was tested using historical TSPO databases from two academic institutions (*i.e.*, the *Centre for Neuroimaging Sciences at King's College London (KCL)* and the *Athinoula A. Martinos Center of Biomedical Imaging, Massachusetts General Hospital (MGH)*) on a total of 323 human brain PET scans, from 5 different PET scanners, and utilizing three TSPO tracers (*i.e.*, [¹¹C]PBR28, [¹⁸F]DPA-714, and [¹¹C]-(R)-PK11195). Firstly, the model was defined, optimized, and tested on [¹¹C]PBR28 data from healthy controls and patients with brain disorders. Specifically, the physiological topology of the brain TSPO density was investigated in healthy conditions while the ability of the model to unveil alterations in regional

neuroinflammatory load was tested for different published studies on patients with risk of psychosis and schizophrenia³⁵, Alzheimer's disease³⁶, and a chronic pain condition (i.e. fibromyalgia³⁷), as well as on a target blocking³⁸ and a test-retest study³⁶. Then, the possibility of generalizing the model to different TSPO tracers was evaluated on [¹⁸F]DPA-714 and [¹¹C]-(R)-PK11195 PET scans on healthy volunteers, individuals with mild cognitive impairment³⁹, and depressive disorder patients⁴⁰. Finally, the ability of the logistic model to unveil the TSPO PET signal increase linked to brain inflammation was tested on a rat model of lipopolysaccharide (LPS) induced neuroinflammation.

2. Materials and Methods

2.1. Logistic regression model

Our novel approach for TSPO PET quantification exploits the theory of logistic regression models⁴¹. These regression approaches allow the prediction of the probability p that a given input belongs to a particular class based on a set of covariates describing that specific input. This is done by adopting a logistic function that transforms the linear combination of the input variables into a probability p ranging between 0 and 1. The mathematical formulation of the model is reported in **Eq.1**, where X_j and β_j represents respectively the j -th input covariate and its corresponding coefficient, β_0 represents the model intercept, n is the number of input covariates, and $\ln$ represents the natural logarithm function.

$$\ln\left(\frac{p}{1-p}\right) = \beta_0 + \sum_{j=1}^n \beta_j X_j \quad (\text{Eq.1})$$

Once the model coefficients have been estimated, the model can be adopted to predict the probability p on new data with the following equation:

$$p = \frac{e^{(\beta_0 + \sum_{j=1}^n \beta_j X_j)}}{1 + e^{(\beta_0 + \sum_{j=1}^n \beta_j X_j)}} \quad (\text{Eq.2})$$

This approach is generally adopted in classification tasks: upon selection of a threshold for the probability p of the input belonging to a specific class (p_{TH}), we assign the input to the class (outcome 1) if $p > p_{TH}$, otherwise to the complementary class (outcome 0). Here, we adapted the logistic model for brain TSPO PET imaging, to distinguish between regions with normal TSPO expression (outcome 0) from regions with TSPO overexpression (outcome 1). The probability distribution of the latter is hence used as a proxy of neuroinflammatory load.

The model relies on the following assumptions:

1. The higher the PET signal measured by the scanner in a given volume of the brain, the higher the concentration of radiotracer in that volume.
2. The overall concentration of the tracer in a given volume of brain is the sum of many components, which include the inflammatory status of brain parenchyma as well as the tracer perfusion and extraction through the brain barriers and non-displaceable binding in the tissue.
3. The explicit modeling of TSPO tracer kinetics through individual covariates allows us to explain the variability of constitutive TSPO signal, and to distinguish between normative conditions and altered states.
4. The effect of each covariate – including age, sex, genotype, and the ratio between injected dose and subject's weight - is equivalent for all the regions across the brain and cerebellum cortex (model coefficients are fixed for all regions).

These assumptions translate into a logistic model that takes as predictors the brain regional TSPO TAC and provides the probability of a specific region manifesting an overexpression of TSPO (p_{TSPO}). Additional predictors, representing possible confounders for the brain TSPO signal, included a measure of the regional tracer blood-to-brain delivery rate provided by the kinetic parameter K_1 , computed with a novel noninvasive methodology adopting an image-derived input function (IDIF)⁴², and a set of individual covariates including age, sex, TSPO genotype (HAB and MAB), and the injected dose normalized for patient weight. A schematic representation of the logistic regression model can be found in **Figure 1**.

Operationally, the proposed methodological framework involves two main steps. Firstly, the logistic regression model is trained on a population of healthy controls (HCs) for the classification of regions of interest (ROIs) with known TSPO expressions, organized into two

separate classes with constitutive low and high TSPO expression and representing regions with low or high measured TSPO PET signal, respectively. As previously described, the classification will be based on the parameter p (Eq. 2), which will be indicated as p_{TSPO} , representing the probability for the region of interest to manifest a high expression of TSPO. Once the model coefficients are defined, the logistic regression can be applied to unseen data (either new PET scans of independent subjects or brain region TACs not included in the model), where for a given TAC, it returns p_{TSPO} , which is used as the main parameter of interest. Conceptually, this is similar to the supervised clustering approach already used in TSPO PET studies²⁴. Both approaches use a pre-defined set of classes with known TSPO density as a proxy of normal and inflamed brain tissues. However, while with supervised clustering the tissue classification focuses on identifying a tissue with low TSPO density to be used as a reference region for tissue modeling, here the classification turns into an indirect quantification of TSPO density.

[insert Figure 1]

2.2. Study participants and datasets

A total of 323 TSPO PET scans were included in this study. Data included five datasets of [¹¹C]PBR28, [¹⁸F]DPA-714, and [¹¹C]-(R)-PK11195 dynamic PET scans gathered from *King's College London (KCL)* and *Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital (MGH)* historical databases. Information for each of the five datasets is summarized in **Table 1**; additional details can be found in **Supplementary Materials S1**. Each study was approved by local ethics committees and institutional review boards before starting, including the *Queen Square London Ethical Committee*, *South Central Berkshire NRES Committee*, *Hammersmith Research Ethics Committee*, *London-Bloomsbury ethics committee*, *National Research Ethics Service Committee East of England Cambridge Central*, and the *UK Administration of Radioactive Substances Advisory Committee* for KCL data, the institutional review board, the *Radioactive Drug Research Committee*, the *Food and Drug administration* and the *Partners Human Research Committee* for MGH data. All the studies were conducted in accordance with the *Declaration of Helsinki*, and all participants provided informed consent to participate. Despite differences across imaging sites in scanner types, data acquisition, and PET reconstruction parameters, all protocols included a continuous

dynamic acquisition (90 or 60 minutes duration) following a bolus injection of the tracer. PET data were corrected for random and scattered coincidences and tissue attenuation. Given the genetic rs6971 polymorphism of the TSPO gene^{31,43}, all participants scanned with [¹¹C]PBR28 or [¹⁸F]DPA-714 were genotyped before scanning, and no LABs were included in the original studies. Structural T1-weighted (T1w) Magnetic Resonance (MR) images were also acquired for each participant and used for image processing and atlas-based anatomical brain segmentation.

2.3. Image preprocessing

For all scans, after preprocessing of dynamic PET images, the *CIC* atlas version 2.0⁴⁴ was adopted for the extraction of regional TACs. An image-derived input function (IDIF) was also extracted, following the approach described in⁴². Finally, regional tracer delivery rate (kinetic microparameter K_I) was computed for each ROI by application of a recently developed non-invasive and simplified methodologic framework consisting of fitting the first minutes (within 10 minutes) of the tracer kinetics in the tissue with a simplified compartmental model with 1 single irreversible compartment and IDIF⁴². Further details on image preprocessing and analysis are provided in **Supplementary Materials S2**.

2.4. Validation of the logistic regression with [¹¹C]PBR28 PET imaging

Model training

A TSPO expression map was derived from mRNA data of 6 post-mortem brains from the *Allen Human Brain Atlas* (https://human.brain-map.org/microarray/search/show?exact_match=false&search_term=%22TSPO%22&search_type=gene) with the *Abagen* toolbox using the *CIC* volumetric atlas in MNI space. TSPO expression map allowed for the investigation of the topological pattern of TSPO expression and the identification of a subset of ROIs with the lowest (*low-expression ROIs*)

and highest (*high-expression ROIs*) TSPO expression to be adopted for model training, with pre-assigned outcomes 0 (*i.e.*, non-inflamed class) and 1 (*i.e.*, inflamed class), respectively.

The training was performed on a dataset of 72 [¹¹C]PBR28 PET scans of HCs (Dataset 1).

The model regressors included:

- a) Regional TACs time samples; each ROI TAC was normalized to standardized uptake value (SUV) to correct for differences in dose-over-weight ratio and then interpolated on a sparser time grid ([1.25 4.5 13.5 30 50 75] min) to reduce collinearity between variables
- b) Regional K_1 estimates to account for tracer blood-brain delivery
- c) Subjects' age, sex, and genotype to account for individual characteristics associated with TSPO variability
- d) Tracer dose over subjects' weight ratio to account for experimental differences

A stepwise feature selection was performed to select the most informative predictors.

Once the model set-up was optimized, the logistic model was trained and tested on [¹¹C]PBR28 PET scans on 72, 27, and 26 HCs from three independent datasets (Dataset 1, Dataset 2, and Dataset 3). Specifically, the pooling of multisite data opened the necessity to deal with possible batch effects. A hierarchical model was thus adopted, with the inclusion of a *random effect* in the logistic regression model, to account for eventual differences due to the scanner and protocols used for the acquisition of the three datasets^{45,46}.

Model performance was evaluated in terms of accuracy, sensitivity, and specificity of classification for all the hierarchical and non-hierarchical models. Details on feature selection, model validation, and post hoc analyses on model covariates are provided in **Supplementary Materials S3 and S4**.

Application to healthy controls

A leave-one-out approach was adopted for the application of the model to each HC. The model was applied for the prediction of the probability $\mathbf{p}_{\text{TSPO}}$ for all the ROIs belonging to the cortex and cerebellum (CC ROIs). Hence, the ROIs average $\mathbf{p}_{\text{TSPO}}$ across HCs for each dataset was correlated with the measure of TSPO expression provided by mRNA data from the Allen Human Brain Atlas, to assess $\mathbf{p}_{\text{TSPO}}$ ability to serve as a proxy of cortical TSPO density in healthy brain.

Applications to pathological conditions

To evaluate the actual feasibility of adopting ROIs $\mathbf{p}_{\text{TSPO}}$ as a biomarker of regional neuroinflammatory load in clinical populations, the logistic regression approach was applied to [^{11}C]PBR28 data acquired in ultra-high-risk of psychosis (UHR), schizophrenia (SCZ), Alzheimer's disease (AD), and fibromyalgia (FM) patients as well as to data acquired with TSPO blocking agent XDB173. A reproducibility analysis was also conducted on test-retest [^{11}C]PBR28 data from AD patients. This step aimed to test the ability of the metric $\mathbf{p}_{\text{TSPO}}$ to unveil changes in TSPO density and replicate results from previous studies. A summary of the information for each group is reported in **Supplementary Table 1**.

Based on the findings reported in the original references, we expected to find:

- Increased TSPO expression in total, frontal, and temporal gray matter for UHR and SCZ compared to controls^{35,47}
- Modest widespread cortical increase in TSPO density, with the most pronounced elevation in the frontal and parietal lobes, for FM patients compared to HCs³⁷
- Increased TSPO density in AD patients compared to controls in frontal, parietal, temporal, and occipital regions⁴⁸; no increase was reported for cerebellum¹²
- Widespread reduction of tracer-specific binding following XBD173 administration³⁸.

Between-group differences in CC ROIs $\mathbf{p}_{\text{TSPO}}$ were analyzed by qualitative comparison of $\mathbf{p}_{\text{TSPO}}$ distributions (histograms normalized as relative probability) and by testing of statistical differences between the distributions with a non-parametric test – *i.e.*, the Wilcoxon rank sum test or the Wilcoxon signed-rank test when a paired test was necessary (*e.g.*, for the XBD173 blocking study). For each study, a deviation distribution was also computed as the between-groups bin-by-bin difference (case group less control group) of the groups' relative probability histograms of the CC ROIs $\mathbf{p}_{\text{TSPO}}$. At this point, a measure of the magnitude of between-group deviation of CC ROIs $\mathbf{p}_{\text{TSPO}}$ (Δ_p) was defined as the percentage sum of the difference distribution for $\mathbf{p}_{\text{TSPO}}$ values higher than 0.5. The Δ_p provides a measure of increase of the relative probability of high $\mathbf{p}_{\text{TSPO}}$ values (higher than 50% probability) for the case group with respect to the control group. Finally, a non-parametric Cohen's d-consistent effect size (γ) was adopted for the quantification of between-group differences in regional $\mathbf{p}_{\text{TSPO}}$ estimates, given the non-Gaussianity of group $\mathbf{p}_{\text{TSPO}}$ distributions. The mathematical formulation of γ is

provided by Lin and colleagues⁴⁹. Unlike traditional effect sizes like Cohen's d , which rely on means and standard deviations, γ focuses on quantiles and dispersion measures that are less sensitive to non-normality (*e.g.*, the median and median absolute deviation) and is thus more suitable to accommodate non-Gaussian skewed distributions. The γ effect is also consistent with Cohen's d in the case of normal distributions. In the case of non-independent distribution, a paired version of the γ effect size was adopted.

Comparison of CC ROIs p_{TSPO} distribution was also repeated for each brain lobe (frontal, temporal, parietal, and occipital lobe), as well as for cerebellum ROIs.

In order to test the reproducibility of model estimates, distributions of CC ROIs p_{TSPO} from test-retest data on AD patients³⁶ were compared, and the intraclass correlation coefficient (ICC) was computed between test and retest p_{TSPO} estimates for each CC ROI.

2.5. Expanding the logistic regression model to [¹⁸F]DPA-714 and [¹¹C]-(R)-PK11195 PET imaging

The hierarchical logistic regression model was applied to all 5 datasets, expanding the model to the quantification of [¹⁸F]DPA-714 and [¹¹C]-(R)-PK11195 data. The previous model setup, in terms of both TACs subsampling and feature selection, was maintained since the small sample size did not allow for tracer-specific training and optimization of the model. The genotype predictor was set to 1 (HAB class) for [¹¹C]-(R)-PK11195, as the tracer is not susceptible to TSPO polymorphism³¹. The hierarchical model was adopted for the prediction of CC-ROIs p_{TSPO} for all HCs (with a leave-one-out approach, excluding the test subject from the training set) and patients (after training the model on all the HCs). The logistic model was thus applied to cross-sectional analyses - by comparison of ROIs p_{TSPO} - of 2 studies: the analysis of differences between carriers of the p.R47H genetic variant of the triggering receptor expressed on myeloid cells 2 immune receptor (TREM2) and non-carriers with mild cognitive impairment (MCI) from [¹⁸F]DPA-714 Dataset 4; the study of mild/moderate depressed subjects (MD) from [¹¹C]-(R)-PK11195 Dataset 5. Details on compared groups for each study are reported in **Supplementary Table 2**.

Consistently with literature findings, we hypothesized (1) a widespread mild reduction of TSPO signal, as well as a focal reduction in brain regions consistent with pathology of Braak

II (*i.e.*, hippocampus) and Braak III stages (*i.e.*, posterior parahippocampal gyrus) in TREM2 patients compared to MCI³⁹, and (2) a modest increase (given the range of Cohen's reported in⁴⁰) of TSPO signal in the insula, prefrontal cortex (PFC), and anterior cingulate cortex (ACC) in depressed subjects compared to HCs. Consequently, distributions of CC ROIs **ptspo** were compared between the MCI and TREM2 groups, and ad hoc analyses of differences in **ptspo** for Braak II and Braak III regions were performed. Concerning the depression study, **ptspo** of insula, PFC, and ACC was compared between the depressed and HC groups.

2.6. Model application to the LPS rat model

Data included a total of 20 dynamic [¹⁸F]DPA-714 brain PET scans on rats gathered from a previous study of LPS-induced neuroinflammation⁵. The first dataset included 4 PET scans carried out 4 days after intracerebral (ic) administration of LPS from *Escherichia coli* 0111: B4 (Sigma) (*ic-LPS*) into the right dorsal striatum. The second dataset included 8 PET scans carried out around 24 hours after peripheral administration of LPS with intraperitoneal (ip) injection (*ip-LPS*) and 8 control scans performed 24 hours after ip vehicle injection (*Vehicle*). More details on experimental protocols, data acquisition, and image analyses can be found in the original reference⁵. Overall, the data analysis focused on 13 ROIs TACs extracted for each animal using the 3D rat brain atlas template as employed by the VivoQuant 2.0 (Invicro LLC) software.

Previous evidence has shown that the *ic-LPS* striatal injection challenge induces a robust focal inflammatory lesion in the ipsilateral hemisphere, while the contralateral side shows no inflammatory reaction^{5,50}. Model training was thus performed on *ic-LPS* scans. A subset of the 13 ROIs in the ipsilateral side of the lesion and the respective ROIs in the contralateral (non-lesioned) side were assumed as *high- and low-expression ROIs*, respectively. Specifically, TACs AUC was compared between the two hemispheres for each brain ROI with a paired t-test, and ROIs showing a statistically significant difference in the TAC AUC after false discovery rate (FDR) correction for multiple comparisons were selected for model training. Starting from the logistic regression model setup and features selection adopted in human studies, the model was further simplified by the exclusion of age and sex (which were standardized in the group of animals) but also genotype from model predictors. After model

training, given the small sample size of the *ic-LPS* training set, the significance of predictors was tested by application of the Wald test.

The model was applied for the computation of brain ROIs p_{TSPO} for *ip-LPS* and *Vehicle* scans. Then, regional p_{TSPO} estimates were compared between the two groups for each ROI by application of the Wilcoxon rank-sum test and FDR correction for multiple comparisons.

3. Results

3.1. Logistic regression model for [^{11}C]PBR28 PET quantification

Model training

Analysis of the topological pattern of TSPO gene expression (**Figure 2**), derived from the data of the Allen Human Brain Atlas, reveals high TSPO expression in subcortical regions, particularly in the pallidum and thalamic regions. Brain cortex ROIs exhibit lower but highly variable levels of gene expression. The cerebellum shows low, though not negligible, TSPO expression, except in the medial regions. Following this pattern, the occipital lobe, along with the dorsal and ventrolateral regions of the cerebellum, were selected as *low-expression ROIs*, while the thalamic and pallidus regions as *high-expression ROIs*. These regions, which are expected to manifest respectively low and high density of TSPO in physiological conditions, were used to train the logistic model. Starting from the initial selection of model predictors (i.e. ROIs TACs samples at 1.25, 4.50, 13.50, 30, 50, and 75 minutes as well as ROIs K_I and subjects' age, sex, genotype, and tracer dose over subjects' weight ratio), the set of features resulting as significant predictors after feature selection included ROIs TAC samples at 1.25, 13.5 and 50 minutes, together with age, genotype, and the K_I microparameter. Notably, sex resulted in a non-significant predictor. Both hierarchical and non-hierarchical models showed good classification performances in terms of accuracy (>0.9), sensitivity (>0.8), and specificity (>0.8) (**Supplementary Figure 1**).

[insert Figure 2]

Validation in healthy controls

To evaluate the ability of the logistic regression approach to provide a physiological measure of TSPO density, firstly the model was applied to the quantification of [^{11}C]PBR28 scans on HCs employing a leave-one-out approach for model training and prediction. Results of leave-one-out training show low variability among the various iterations in model coefficient estimates (coefficient of variation $\text{cv}=1.5\pm0.4\%$; $\text{mean}\pm\text{std}$ across model predictors), as represented in **Figure 3a**. Coefficients related to ROI TAC samples are the highest in absolute value, particularly for samples at 13.5 minutes ($t\text{stat}=-20.9$) and 50 minutes ($t\text{stat}=24.9$). However, while the model coefficient shows a positive sign for the TACs sample at 50 min, an inverse relationship is reported for the early samples of tissue kinetics. Lower but non-negligible contribution is given by age ($t\text{stat}=-9.5$), genotype ($t\text{stat}=-15.31$), and K_I predictors ($t\text{stat}=-13.35$).

As expected, in a healthy condition the predicted pTSPO shows values close to zero and 1 respectively for the *low-* and *high-expression ROIs*, as clearly visible from histograms of pTSPO for the HC cohorts of the three different [^{11}C]PBR28 datasets (Dataset 1, 2 and 3) reported in **Figure 3b**. Histograms of CC ROIs pTSPO , on the other hand, show high variability in the pTSPO values. This variability partially reflects the topological pattern of TSPO gene expression in the brain, as shown by the high correlation between the across-subjects average of CC ROIs pTSPO and the pattern of gene expression from the Allen Human Brain Atlas for each of the three HC cohorts (Dataset1: $\rho=0.47$; Dataset2: $\rho=0.41$; Dataset3: $\rho=0.48$, all $p<0.05$; **Figure 3c**).

[insert Figure 3]

Validation in clinical populations

Consistent with the study hypothesis, the comparison of group distributions for CC ROIs pTSPO (**Figure 4**) shows statistically significant increases in UHR, SCZ, AD, and FM patients with respect to HCs. In contrast, cortical and cerebellar pTSPO demonstrates a significant reduction after target blocking via XBD173 administration. The magnitude of between-group deviations

Δ_p and the effect size γ revealed the highest deviation in the case of XBD173 blocking ($\Delta_p=-52\%$, $\gamma=-1.3$), followed by AD ($\Delta_p=+32\%$, $\gamma=1.2$), SCZ ($\Delta_p=+29\%$, $\gamma=1.0$), and UHR ($\Delta_p=+18\%$, $\gamma=0.5$) patients; a mild effect was reported for FM patients ($\Delta_p=+13\%$, $\gamma=0.3$).

Between-group comparisons of CC ROIs **pts_{PO}** for each anatomical lobe show a significant increase for the UHR, SCZ, and AD with respect to HCs and a significant decrease in the case of XDB173 blocking for all four lobes (**Supplementary Figure 3**). FM patients show a significant increase only in the frontal, occipital, and parietal lobes. In all studies, significant differences were also found when comparing cerebellum **pts_{PO}** between the two groups.

The analysis of test-retest data on AD patients showed high reproducibility both in terms of the similarity of CC ROIs **pts_{PO}** histograms (Wilcoxon rank sum test $p\text{-value}>0.05$, $\Delta_p=-2\%$) and ICC, with 74% ROIs having $\text{ICC}\geq 0.7$ (**Supplementary Figure 4**).

Comparison with previous evidence in terms of the effect size of between-group differences for each case study is summarized in **Supplementary Table 3**.

[insert Figure 4]

3.2. Expanding the hierarchical model to [¹⁸F]DPA-714 and [¹¹C]-(R)-PK11195

Re-training without feature optimization of the hierarchical model with the inclusion of HC cohorts from [¹⁸F]DPA-714 and [¹¹C]-(R)-PK11195 datasets gave consistent results to the [¹¹C]PBR28 model training (**Figure 5**). Coefficient estimates show a comparable pattern to the one obtained from training on [¹¹C]PBR28 HCs in terms of coefficients sign, absolute value, and variability among leave-one-out estimates. As for the [¹¹C]PBR28 model, histograms of predicted ROIs **pts_{PO}** in HCs of each of the five datasets show values respectively close to zero and 1 for the *low*- and *high-expression ROIs*, and relatively low but highly variable values for CC ROIs **pts_{PO}**. Across-subjects average of CC ROIs **pts_{PO}** shows a good correlation to the regional level of TSPO gene expression (Dataset 1: $\rho=0.46$; Dataset 2: $\rho=0.41$; Dataset 3: $\rho=0.49$; Dataset 2: $\rho=0.62$; Dataset 3: $\rho=0.56$).

Results of model application to cross-sectional analysis on [¹⁸F]DPA-714 (Dataset 4) show a significant but modest increase of CC ROIs **pts_{PO}** for the TREM2 with respect to the MCI group (Wilcoxon rank sum test $p\text{-value}<10^{-5}$, $\Delta_p=+6\%$) and no statistical difference when comparing Braak2 and Braak3 regions, differently from the original publication. Cross-

sectional analysis of [^{11}C]-(*R*)-PK11195 scans showed a modest increase of **ptspo** of insula ($\gamma=0.1$), PFC ($\gamma=0.6$), and ACC ($\gamma=0.1$) for depressed subjects compared to HCs but none of these regions reach statistical significance due to the high intersubject variability in **ptspo** (IQR= interquartile range; insula: IQR_{HC} = [0.128 0.497], IQR_{MD} = [0.143 0.374]; PFC: IQR_{HC} = [0.111 0.526], IQR_{MD} = [0.169 0.443]; ACC: IQR_{HC} = [0.097 0.568], IQR_{MD} = [0.123 0.379]).

[insert Figure 5]

3.3. Model application to the LPS rat model

ROIs TACs AUC showed significant differences between the ipsilateral and contralateral hemispheres for cortex, basal ganglia, corpus callosum, amygdala, septal area, ventricles, and white matter (**Figure 6a**). These regions were thus employed for model training. Only the TAC sample at 13.5 min resulted as a statistically significant predictor from the Wald test ($z\text{-score} > 1.96$) and was included in the final model. Model application to LPS and vehicle ip-administered rat scans showed a significant increase in **ptspo** values in the *ip-LPS* with respect to the *Vehicle* group (**Figure 6b**).

[insert Figure 6]

4. Discussion

We developed a novel TSPO PET analytical framework that exploits the raw PET signal to provide a statistical measure of brain TSPO density. We tested it on multiple TSPO radiotracers, scanners, and imaging facilities, replicating literature findings in different (even if not all) clinical cohorts. The method does not utilize blood-based kinetic modeling and requires dynamic scanning of a maximum of 60 minutes from tracer injection, reducing experimental time.

Proposed improvements

The proposed analytical framework could potentially address the following limitations of standard TSPO PET quantification:

1. In contrast to standard kinetic modeling, the method does not require any arterial blood samples, nor laborious procedures for the quantification of plasma tracer activity and the correction of metabolite radioactivity. The use of the *ITIK-IDIF* method⁴² allowed for a non-invasive estimation with an IDIF of the K_1 microparameter.
2. The approach does not require the identification of a reference region, which is particularly challenging for TSPO PET imaging, and, as it avoids any normalization for the reference TAC, helps in the identification of mild global effects related to a disorder. Even when more sophisticated data-driven approaches like supervised clustering are adopted for the identification of the reference region, the identified region is often still contaminated at some level by specific binding of the tracer.
3. The inclusion in the model of the K_1 microparameter - despite limitations of the *ITIK-IDIF* approach adopted for the estimation⁴² - allows taking into account possible alterations of the tracer delivery rate linked to modulation of cerebral blood flow or BBB permeability in pathological conditions. Interestingly, the model coefficient for K_1 shows an inverse association between tracer blood-to-brain exchange K_1 and the **ptsPO**, indicating that lower tracer delivery values are associated with a higher inflammatory load. This is consistent with the theory linking peripheral with central inflammation proposed by Turkheimer et al³⁰.
4. The adoption of a regression approach, with genotype and age included as model predictors, allows us to explain part of the inter-individual variability in the TSPO PET signal in both physiological and pathological conditions that limits the tracer statistical power in assessing the presence and progression of neuroinflammation in clinical applications.
5. The definition of a hierarchical model allows the modeling of possible batch effects linked to differences in scanners and protocols adopted for data acquisition.

The proposed methodology has the potential to serve as a standardized tool for neuroinflammation assessment, facilitating its integration into clinical research and potentially into routine clinical practice for more personalized and accurate diagnosis and/or monitoring of neuroinflammatory conditions.

Highlights from HC analysis

The validation of the logistic regression model (both hierarchical and non-hierarchical) shows excellent performance of classification of *low*- and *high-expression ROIs* in HCs in terms of specificity and sensitivity of the model. The preliminary interpolation of the ROI TACs on a less dense time grid allows for a reduction of the number of model predictors but also of possible problems of collinearity between variables. The stepwise feature selection analysis allows for further reduction in the number of variables and possible overfitting issues.

The application of the approach to the quantification of [¹¹C]PBR28, [¹⁸F]-DPA714, and [¹¹C]-(*R*)-PK11195 on healthy control scans showed a good concordance between the pattern of TSPO expression predicted by the model and the topology of gene expression defined by mRNA data from the Allen Human Brain Atlas. Previous studies have already investigated the concordance between PET imaging and genetic data on regional TSPO expression with inconsistent results^{51,52}. This new quantification approach can map constitutive TSPO density better than any previous quantification method. The model demonstrated the ability to replicate the expected topological pattern of TSPO in healthy individuals.

The training of the hierarchical model on [¹¹C]PBR28 data, as well as the retraining of the hierarchical model with the inclusion of [¹⁸F]DPA-714 and [¹¹C]-(*R*)-PK11195 HC scans, gave consistent results, both in terms of CC ROIs **p_{TSPO}** distributions and model coefficient estimates. Specifically, the analysis of model coefficient estimates provides some insights into the model. Given comparable brain regional inflammatory status and TSPO concentration, the model covariates ensure the balancing of regional **p_{TSPO}** estimates obtained under different conditions of aging, tracer affinity, and tracer delivery. In practice, the negative sign of the β coefficients for age, genotype and K_I predictors indicates that, given the same level of TSPO PET signal, the model will give as output lower **p_{TSPO}** estimates at increasing subject's age (to compensate for increases in TSPO uptake linked to age), at increasing tracer delivery (to compensate for the higher availability of tracer in parenchyma) as well as lower values for HAB with respect to MAB participants (to compensate for a higher tracer affinity, and thus measured radioactivity in brain parenchyma). The magnitude of model coefficients, which are optimized with the training of the model, determines the strength of this regularization.

Cross-sectional analysis on [¹¹C]PBR28 data

The application of the method to cross-sectional analyses on [¹¹C]PBR28 data gave promising results, replicating evidence from previous studies for different cohorts and showing good reproducibility of ROIs **ptspo** estimates. As expected from previous evidence³⁵, a widespread increase in TSPO density was reported in the whole cortex when comparing ultra-high-risk of psychosis and schizophrenia patients to healthy controls. Similarly, a reduction in the whole brain TSPO PET signal was shown after XDB173 target blocking³⁸. An increase in **ptspo** reflecting an increase in TSPO density for frontal, parietal, temporal, and occipital lobes was reported for Alzheimer's disease patients in line with previous general references¹². Regarding fibromyalgia patients, a widespread gray matter **ptspo** increase and an increase for frontal and parietal lobes were shown, in line with the results from the original reference³⁷. In all cases, computed γ effect sizes show consistent group effects with previous evidence, despite slight variations in their magnitude due to intrinsic differences in markers and quantification approaches employed.

TSPO expression in the cerebellum

It is worth mentioning that, in all the [¹¹C]PBR28 cross-sectional studies performed, statistically significant differences between groups in cerebellum ROIs **ptspo** were reported. Given the ubiquitous expression of TSPO in the brain, no anatomical region has been demonstrated to completely lack any specific binding to the target. The cerebellum has often been adopted as a pseudo-reference region for the computation of relative measures of TSPO load and has been validated for use in Alzheimer's disease studies⁵³. However, given the high cellular heterogeneity and TSPO displacement, the cerebellum may not represent an ideal reference region for TSPO PET imaging studies, and its adoption should be carefully checked for each brain condition³⁸. The cerebellum is also close to the confluences of sinuses, where increases in TSPO PET signal, possibly from cerebrospinal fluid coming out of the inflamed brain, have been found to be associated with both central and peripheral inflammation²⁸.

Extension to other tracers

While the logistic model successfully detected TSPO alterations in cross-sectional studies with [^{11}C]PBR28 data, we were not able to fully replicate results for [^{18}F]DPA-714 and [^{11}C]-(*R*)-PK11195 datasets. This discrepancy could be due to several factors. First, the sample size was relatively small, with only 8 [^{18}F]DPA-714 scans for the TREM2 carriers and mild cognitive impaired subject groups, and only 25 healthy controls for [^{11}C]-(*R*)-PK11195 data. Second, the model settings – ranging from the time grid adopted for TACs subsampling to the selection of features – were optimized specifically for [^{11}C]PBR28 and could be suboptimal for the quantification of [^{18}F]DPA-714 and [^{11}C]-(*R*)-PK11195. Differences between tracers extend beyond variations in affinity to the specific pharmacokinetics of each tracer as well as its dependencies on genetic polymorphism, thus opening the necessity for the development of tracer-specific optimization and training of the model. Consequently, the possibility of adopting the model for the quantification of TSPO density from [^{18}F]DPA-714 and [^{11}C]-(*R*)-PK11195 should be further explored. Larger cohorts of HCs and patients will be necessary for model optimization and training on [^{18}F]DPA-714 and [^{11}C]-(*R*)-PK11195 data. Finally, it is worth mentioning that original studies for both the TREM2 and the depression cohorts reported very mild alterations in TSPO density; testing the method on new cohorts with evidence of stronger effects of the disease will help to clarify the actual feasibility of expanding the method to other TSPO tracers.

Model application to the LPS rat model

A slightly different approach was adopted for the application of the logistic regression method to rat models of neuroinflammation to account for differences between species and adapt the model to the peculiar experimental protocol. Regional TACs derived from ic-LPS scans from ipsilateral (lesioned) and contralateral (non-lesioned) hemispheres - with respect to LPS ic-injection – provide examples of [^{18}F]DPA-714 kinetics from inflamed and not-inflamed regions, respectively, and were thus adopted for model training. Despite the small sample size of the ic-LPS dataset, this choice guaranteed a more controlled setting for the training of the logistic regression model, as the reference classes for TSPO constitutive expression (class 0) and overexpression (class 1) were histologically validated. Moreover, given the standardized

characteristics of rats, sex and age were not included as model predictors, simplifying the model construction and, therefore, its parameter identification.

Despite the simplifications and the small sample size of the training set, the logistic regression model replicated the regional pattern of TSPO expression in vehicle scans reported in the original reference⁵. Additionally, the model allowed us to unveil the expected widespread increase in brain inflammatory load 24h after the intraperitoneal LPS challenge, corroborating the original results.

Limitations and future directions

The use of pre-existing data, which were collected with the use of different scanners and specific acquisition protocols, represents a limitation of this study. Image characteristics in terms of spatial and temporal resolution and signal-to-noise ratio would particularly affect the IDIF extraction and 1T1K-IDIF K_1 estimation. However, the use of a hierarchical model allowed us to partially account for possible differences linked to discrepancies in data collection. Moreover, cross-sectional analyses were always conducted between scans sharing the same scanner and acquisition protocol. The only exception was represented by the shorter acquisition length of [¹¹C]PBR28 AD scans, with only 60 minutes against the 90 minutes of acquisition of the HC group, despite general analogies between the acquisition protocols and the use of the same scanner for the data collection. Since the final configuration of the designed model included only TAC samples corresponding to the mid-frame time of 1.25, 13.5, and 50 minutes, we were still able to apply the logistic regression method to the AD cohort.

Regarding quantification, different modeling approaches (from blood-based to reference region methods) were employed as reference standards, according to the specific aims and experimental designs of each original study. Due to the lack of methodological standardization and the high heterogeneity inherent in TSPO PET imaging analysis, future research should systematically assess the consistency of results across various quantification methods. Such an investigation, however, was beyond the scope of the present study.

Another general limitation of the study concerns model assumptions. By design, the model assumes a consistent effect of the covariates across regions. This limitation is inherent to the methodology itself, as the model training on healthy control scans requires the simultaneous inclusion of a subset of brain regions with either very low or very high expected TSPO expression, serving as a proxy for non-inflamed or inflamed regions, respectively. This leads

to the identification of a single model for the regional prediction of the **ptspo** parameter. Performing a region-specific training of the logistic regression model would require the availability and adoption of TSPO PET scans with a known absence or presence of a chronic inflammatory response for each specific region of interest. Being aware of the limitations of this approach, the model was designed to be applied only to cortical regions of the brain and cerebellum, where a more homogeneous effect of model covariates is reasonably expected. Nevertheless, alternative normative modelling and more complex methodological frameworks, allowing for a regional modulation of model coefficients, should be explored in future works. Similarly, different formulations accounting for possible non-linear relationships and interactions between covariates should be tested. The model could also be improved with the inclusion of further covariates such as BMI, stress, and the presence of comorbidities, which were not available for the data under study but could represent significant factors affecting brain TSPO load. Moreover, additional data and analyses will be fundamental to test the possibility of extending the methodological framework from ROI- to voxel-wise quantification and derive parametric maps of TSPO density. Furthermore, the analysis of subject-specific distributions of **ptspo** metrics could allow for the derivation of individual scores of neuroinflammation, but this would require additional investigation.

It must also be highlighted that the Allen Human Brain Atlas gene expression data – adopted for model validation - have been derived from only six postmortem adult brains, with data related to the right hemisphere only available for two donors. This highlights the intrinsic limitation of this data in the investigation of gene expression in the human brain.

A final major limitation concerns the biological interpretation of regional TSPO protein density as a marker of neuroinflammation. Although TSPO PET imaging is widely used to study inflammatory responses across various clinical domains, the biological interpretation of TSPO PET signal elevations is still unclear. Skepticism arises from the lack of cellular specificity of brain TSPO expression: despite being highly expressed in microglia, TSPO is also constitutively expressed by several other cell types, including astrocytes, some neurons, endothelial cells, and infiltrating macrophages^{5,9}. Additionally, a recent study suggested that TSPO overexpression characterizing human neuroinflammatory conditions does not necessarily mirror the proinflammatory activation of microglia cells⁷. Nevertheless, the same study showed that regional TSPO signal elevations correspond closely with increased densities of glial and immune cells⁷. This finding was replicated in other independent post-mortem

work⁹, showing a significant positive correlation between regional [¹¹C]-(R)-PK11195 binding potential ante-mortem and the burden of post-mortem CD68+ phagocytic microglia, as well as microglial TSPO levels. Increases in immune cell density are a well-established hallmark of neuroinflammation, which may involve microglia, as well as other CNS-resident immunocompetent cells (e.g., astrocytes) and recruited peripheral immune cells. However, a recent study in Alzheimer's disease patients reported a significant association between TSPO PET and cerebrospinal fluid inflammatory proteins involved in biological processes related to neurodegeneration and neuroinflammation in Alzheimer's disease⁵⁴, thus confirming that TSPO PET signal elevations are likely mostly driven by microglia. TSPO PET imaging can thus still provide a valuable, even if non-specific, measure of regional neuroinflammatory load. Beyond the debate on the validity of TSPO density and TSPO PET imaging as a marker of neuroinflammation, this work provided an alternative methodological tool that could facilitate the use of TSPO PET imaging in both experimental medicine and clinical trials. Additionally, while the limitation of TSPO as a neuroinflammatory target persists, this approach would remain valid in the event of the development of a better molecular target for imaging neuroinflammation with PET.

Conclusions

We developed a new blood- and reference-free analytical framework for the quantification of regional brain density. Model validation supports the use of the **prtspo** metrics in the study of neuroinflammation and the application of this approach to data collected with different scanners and acquisition protocols. This method could be applied to the quantification of different TSPO tracers, given **an** adequate reference sample size for tracer-specific model optimization and parameter training. Further studies and larger sample sizes are necessary for the optimization of the methodology and the derivation of subject-specific scores of neuroinflammation.

Acknowledgments

We would like to thank the participants who took part in these imaging studies and the scientists who, in the name of collaborative science, provided us with access to their data. We also want to thank Giulia Debiase for helpful discussions on methodology, Alessio Giacomel, for helping with the analysis of gene expression data, Minhae Kim, Erin Morrissey, and Paulina Knight for their support on MGH data collection, and all the radio-pharmacy and nuclear medicine technologists.

Author's contributions

Lucia Maccioni and Mattia Veronese designed the research. Lucia Maccioni, Ludovica Brusafferri, Leonardo Barzon, and Julia J. Schubert processed the data. Lucia Maccioni performed the statistical analyses and realized the figures for the manuscript and supplementary materials. Lucia Maccioni and Mattia Veronese drafted the manuscript. Lucia Maccioni, Ludovica Brusafferri, Leonardo Barzon, Julia J. Schubert, Maria A. Nettis, Oliver Cousins, Ivana Rosenzweig, Yuya Mizuno, Marta Vicente-Rodríguez, Nisha Singh, Tiago Reis Marques, Neil A. Harrison, Tim Fryer, Edward T. Bullmore, Diana Cash, Valeria Mondelli, Carmine Pariante, Oliver Howes, Federico E. Turkheimer, Marco L. Loggia, Mattia Veronese critically revised the manuscript and approved the last version.

Conflict of interest

Dr Howes has received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organized by Abbvie, Alkermes, Angellini, Autifony, Biogen, Boehringer-Ingelheim, Delix, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Jansenn, Karuna, Lundbeck, Merck, Neumora, Neurocrine, Ontrack/ Pangea, Otsuka, Sunovion, Teva, Recordati, Roche, Rovi and Viatrix/ Mylan. He was previously a part-time employee of Lundbeck A/v. Dr Howes and Dr. Veronese have a patent for the use of dopaminergic imaging. All the other authors do not report any relevant conflict of interest.

Funding

Lucia Maccioni is supported by Fondazione Ing. Aldo Gini scholarship. Mattia Veronese is supported by EU funding within the MUR PNRR “National Center for HPC, BIG DATA AND QUANTUM COMPUTING (Project no. CN00000013 CN1), the Ministry of University and Research within the Complementary National Plan PNC DIGITAL LIFELONG PREVENTION - DARE (Project no PNC0000002_DARE), and by Fondo per il Programma Nazionale di Ricerca e Progetti di Rilevante Interesse Nazionale (PRIN), (Project no 2022RXM3H7). Marco Loggia is supported by NIH grants R01NS095937-01A1, R01NS094306-01A1, 1 RM1 NS128741-01, 1R01AR079110-01A1, 1R01DA053316-01, 1R01 DA047088-01, W81XWH-14-1-0543. Federico Turkheimer is funded by the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC)

For the purpose of open access, this paper has been published under a creative common licence (CC-BY) to any accepted author manuscript version arising from this submission. This study was funded by Medical Research Council-UK (MC_U120097115; MR/W005557/1 and MR/V013734/1), UKRI (no. 10039412), EU (no. 101028661 and 101026235), Margaret Temple, King’s Challenge Fund, and Wellcome Trust (no. 094849/Z/10/Z; 227867/Z/23/Z) grants to Dr Howes and the *National Institute for Health and Care Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London*. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health.

Supplementary material

Supplementary material for this paper can be found at <http://jcbfm.sagepub.com/content/by/supplemental-data>.

References

1. Dupont A-C, Largeau B, Santiago Ribeiro M, et al. Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. *IJMS* 2017; 18: 785.
2. Jain P, Chaney AM, Carlson ML, et al. Neuroinflammation PET Imaging: Current Opinion and Future Directions. *J Nucl Med* 2020; 61: 1107–1112.
3. Cosenza-Nashat M, Zhao M-L, Suh H-S, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. *Neuropathology and Applied Neurobiology* 2009; 35: 306–328.
4. Lavis S, Guillermier M, Hérard A-S, et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. *J Neurosci* 2012; 32: 10809–10818.
5. Vicente-Rodríguez M, Singh N, Turkheimer F, et al. Resolving the cellular specificity of TSPO imaging in a rat model of peripherally-induced neuroinflammation. *Brain, Behavior, and Immunity* 2021; 96: 154–167.
6. Vicente-Rodríguez M, Mancuso R, Peris-Yague A, et al. Pharmacological modulation of TSPO in microglia/macrophages and neurons in a chronic neurodegenerative model of prion disease. *J Neuroinflammation* 2023; 20: 92.
7. Nutma E, Fancy N, Weinert M, et al. Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases. *Nat Commun* 2023; 14: 5247.
8. Nutma E, Stephenson JA, Gorter RP, et al. A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis. *Brain* 2019; 142: 3440–3455.
9. Wijesinghe SS, Rowe JB, Mason HD, et al. Post-mortem validation of *in vivo* TSPO PET as a microglial biomarker. *Brain* 2025; awaf078.
10. Cumming P, Burgher B, Patkar O, et al. Sifting through the surfeit of neuroinflammation tracers. *J Cereb Blood Flow Metab* 2018; 38: 204–224.
11. Dimitrova-Shumkovska J, Krstanoski L, Veenman L. Diagnostic and Therapeutic Potential of TSPO Studies Regarding Neurodegenerative Diseases, Psychiatric Disorders, Alcohol Use Disorders, Traumatic Brain Injury, and Stroke: An Update. *Cells* 2020; 9: 870.
12. Kreisl WC, Lyoo CH, McGwier M, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. *Brain* 2013; 136: 2228–2238.
13. Loggia ML, Chonde DB, Akeju O, et al. Evidence for brain glial activation in chronic pain patients. *Brain* 2015; 138: 604–615.

14. Bodini B, Tonietto M, Airas L, et al. Positron emission tomography in multiple sclerosis — straight to the target. *Nat Rev Neurol* 2021; 17: 663–675.
15. De Picker LJ, Morrens M, Branchi I, et al. TSPO PET brain inflammation imaging: A transdiagnostic systematic review and meta-analysis of 156 case-control studies. *Brain Behav Immun* 2023; 113: 415–431.
16. Tonietto M, Rizzo G, Veronese M, et al. A Unified Framework for Plasma Data Modeling in Dynamic Positron Emission Tomography Studies. *IEEE Trans Biomed Eng* 2019; 66: 1447–1455.
17. Tonietto M, Rizzo G, Veronese M, et al. Plasma radiometabolite correction in dynamic PET studies: Insights on the available modeling approaches. *J Cereb Blood Flow Metab* 2016; 36: 326–339.
18. Albrecht DS, Granziera C, Hooker JM, et al. In Vivo Imaging of Human Neuroinflammation. *ACS Chem Neurosci* 2016; 7: 470–483.
19. Turkheimer FE, Rizzo G, Bloomfield PS, et al. The methodology of TSPO imaging with positron emission tomography. *Biochemical Society Transactions* 2015; 43: 586–592.
20. Lockhart A, Davis B, Matthews JC, et al. The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant α_1 -acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker. *Nuclear Medicine and Biology*.
21. Nettis MA, Veronese M, Nikkheslat N, et al. PET imaging shows no changes in TSPO brain density after IFN- α immune challenge in healthy human volunteers. *Transl Psychiatry* 2020; 10: 89.
22. Turkheimer FE, Althubaity N, Schubert J, et al. Increased serum peripheral C-reactive protein is associated with reduced brain barriers permeability of TSPO radioligands in healthy volunteers and depressed patients: implications for inflammation and depression. *Brain, Behavior, and Immunity* 2021; 91: 487–497.
23. Lammertsma AA, Hume SP. Simplified Reference Tissue Model for PET Receptor Studies. *NeuroImage* 1996; 4: 153–158.
24. Schubert J, Tonietto M, Turkheimer F, et al. Supervised clustering for TSPO PET imaging. *Eur J Nucl Med Mol Imaging* 2021; 49: 257–268.
25. Turkheimer FE, Edison P, Pavese N, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. *J Nucl Med* 2007; 48: 158–167.
26. Plavén-Sigra P, Cervenka S. Meta-analytic studies of the glial cell marker TSPO in psychosis – a question of apples and pears?: A commentary on ‘Neuroinflammation in schizophrenia: metaanalysis of in-vivo microglial imaging’ by Marques *et al* . *Psychol Med* 2019; 49: 1624–1628.
27. Werry EL, Bright FM, Piguet O, et al. Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. *IJMS* 2019; 20: 3161.

28. Eifff B, Bullmore ET, Clatworthy MR, et al. Extra-axial inflammatory signal and its relation to peripheral and central immunity in depression. Epub ahead of print 16 March 2024. DOI: 10.1101/2024.03.15.24304342.
29. Erickson MA, Dohi K, Banks WA. Neuroinflammation: A Common Pathway in CNS Diseases as Mediated at the Blood-Brain Barrier. *Neuroimmunomodulation* 2012; 19: 121–130.
30. Turkheimer FE, Veronese M, Mondelli V, et al. Sickness behaviour and depression: An updated model of peripheral-central immunity interactions. *Brain, Behavior, and Immunity* 2023; 111: 202–210.
31. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. *J Cereb Blood Flow Metab* 2012; 32: 1–5.
32. Laaksonen S, Saraste M, Nylund M, et al. Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals. *Front Neurol* 2024; 15: 1352116.
33. Peyronneau M, Kuhnast B, Nguyen D-L, et al. [18F]DPA-714: Effect of co-medications, age, sex, BMI and TSPO polymorphism on the human plasma input function. *Eur J Nucl Med Mol Imaging* 2023; 50: 3251–3264.
34. Tuisku J, Plavén-Sigra P, Gaiser EC, et al. Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study. *Eur J Nucl Med Mol Imaging* 2019; 46: 2329–2338.
35. Bloomfield PS, Selvaraj S, Veronese M, et al. Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [¹¹ C]PBR28 PET Brain Imaging Study. *AJP* 2016; 173: 44–52.
36. Nair A, Veronese M, Xu X, et al. Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease. *EJNMMI Res* 2016; 6: 72.
37. Albrecht DS, Forsberg A, Sandström A, et al. Brain glial activation in fibromyalgia – A multi-site positron emission tomography investigation. *Brain, Behavior, and Immunity* 2019; 75: 72–83.
38. Veronese M, Reis Marques T, Bloomfield PS, et al. Kinetic modelling of [¹¹ C]PBR28 for 18 kDa translocator protein PET data: A validation study of vascular modelling in the brain using XBD173 and tissue analysis. *J Cereb Blood Flow Metab* 2018; 38: 1227–1242.
39. Cousins O, Schubert JJ, Chandra A, et al. Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge. *Journal of Neuroinflammation* 2023; 20: 272.
40. Schubert J, Veronese M, Fryer TD, et al. A Modest Increase in 11C-PK11195-Positron Emission Tomography TSPO Binding in Depression Is Not Associated With Serum C-Reactive Protein or Body Mass Index. *Biol Psychiatry Cogn Neurosci Neuroimaging* 2021; 6: 716–724.

41. Hosmer DW, Lemeshow S, Sturdivant RX. *Applied Logistic Regression*. John Wiley & Sons,
<https://books.google.it/books?hl=en&lr&id=bRoxQBIZRd4C&oi=fnd&pg=PR13&dq=second+edition+Hosmer,+D.+W.,+Lemeshow,+S.,+Applied+Logistic+Regression+%C2%A0John+Wiley+%26+Sons.&ots=kM2Qrm7Qfc&sig=OP0uvASHs-rdEKLWkF0rf-eOA6o#v=onepage&q&f=false> (2013).
42. Maccioni L, Michelle CM, Brusaferrri L, et al. A blood-free modeling approach for the quantification of the blood-to-brain tracer exchange in TSPO PET imaging. *Front Neurosci*; 18. Epub ahead of print 22 July 2024. DOI: 10.3389/fnins.2024.1395769.
43. Kreisl WC, Jenko KJ, Hines CS, et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. *J Cereb Blood Flow Metab* 2013; 33: 53–58.
44. Tziortzi AC, Searle GE, Tzimopoulou S, et al. Imaging dopamine receptors in humans with [11C]-(+)-PHNO: Dissection of D3 signal and anatomy. *NeuroImage* 2011; 54: 264–277.
45. Bryk AS, Raudenbush SW. *Hierarchical linear models: Applications and data analysis methods*. Thousand Oaks, CA, US: Sage Publications, Inc, 1992.
46. Degenholtz HB, Bhatnagar M. Introduction to Hierarchical Modeling. *Journal of Palliative Medicine* 2009; 12: 631–638.
47. Marques TR, Ashok AH, Pillinger T, et al. Neuroinflammation in schizophrenia: meta-analysis of *in vivo* microglial imaging studies. *Psychol Med* 2019; 49: 2186–2196.
48. Zhou R, Ji B, Kong Y, et al. PET Imaging of Neuroinflammation in Alzheimer’s Disease. *Front Immunol*; 12. Epub ahead of print 16 September 2021. DOI: 10.3389/fimmu.2021.739130.
49. Lin T-J, Landry MP. Quantifying Data Distortion in Bar Graphs in Biological Research. Epub ahead of print 24 September 2024. DOI: 10.1101/2024.09.20.609464.
50. Sridharan S, Lepelletier F-X, Trigg W, et al. Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats. *Mol Imaging Biol* 2017; 19: 77–89.
51. Martins D, Giacomel A, Williams SCR, et al. Imaging transcriptomics: Convergent cellular, transcriptomic, and molecular neuroimaging signatures in the healthy adult human brain. *Cell Reports* 2021; 37: 110173.
52. Rizzo G, Veronese M, Tonietto M, et al. Kinetic Modeling without Accounting for the Vascular Component Impairs the Quantification of [¹¹ C]PBR28 Brain PET Data. *J Cereb Blood Flow Metab* 2014; 34: 1060–1069.
53. Lyoo CH, Ikawa M, Liow J-S, et al. Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein. *J Nucl Med* 2015; 56: 701–706.

54. Pola I, Ashton NJ, Antônio De Bastiani M, et al. Exploring inflammation-related protein expression and its relationship with TSPO PET in Alzheimer's disease. *Alzheimer's & Dementia* 2025; 21: e70171.

Titles and legends to figures

Figure 1. Logistic regression model for TSPO PET quantification

The figure reports a schematic representation of the logistic regression model, with the inputs and outputs of the model. The method takes as input ROIs TSPO TACs, ROIs K_I , computed with a novel noninvasive methodology adopting an IDIF, and a set of individual covariates and gives as output ROIs p_{TSPO} . [ROI=region of interest; K_I =blood-to-brain delivery rate; IDIF=image-derived input function; p_{TSPO} = ROI probability of manifesting an overexpression of TSPO]

Figure 2. TSPO gene expression map

The figure shows regional TSPO gene expression derived from the Allen Human Brain Atlas for anatomical ROIs defined by the CIC atlas. A graph showing regional values of gene expression in the left hemisphere is shown on the left. Representative slices of the map of TSPO expression are represented on the right. *Low-* and *high-expression ROIs* are highlighted in the graph.

Figure 3. Leave-one-out training and application to [^{11}C]PBR28 healthy control scans

Panel A reports the results of the coefficient estimates for each predictor: colored bars represent the values of β estimates obtained when training on the whole HC cohort, while error bars represent the variability of estimates between the different iterations of the leave-one-out approach; panel B shows the relative probability of *low-expression* (green), *high-expression* (orange) and CC (yellow) ROIs p_{TSPO} for each of the three datasets; panel C represents correlation between HCs' average CC ROIs p_{TSPO} and the regional TSPO gene expression [HC=healthy control].

Figure 4. Cross-sectional analysis – Comparison of CC ROIs p_{TSPO} relative distribution

Each panel shows, for each study under investigation, the comparison of the group relative probability of CC ROIs p_{TSPO} (on the left) and the difference between the two relative probabilities (on the right) [HC=healthy control; UHR=ultra-high risk of psychosis;

SCZ=schizophrenia; AD=Alzheimer's disease; FM=fibromyalgia; * Wilcoxon (paired or unpaired) test p value<0.0001].

Figure 5. Leave-one-out training and application to [¹¹C]PBR28, [¹⁸F]DPA-714 and [¹¹C]-PK11195 healthy control scans

Panel A reports the results of the coefficient estimates for model training on [¹¹C]PBR28, [¹⁸F]DPA-714, and [¹¹C]-(R)-PK11195 HCs (green), compared to results of training on only [¹¹C]PBR28 data (blue): colored bars represent the values of β estimates obtained when training on the whole HC cohort, while error bars represent the variability of estimates between the different iterations of the leave-one-out approach; panel B shows the relative probability of *low-expression* (green), *high-expression* (orange) and CC (yellow) ROIs **ptspo** for each of the three datasets; panel C represents correlation between the across HCs average of CC ROIs **ptspo** and the regional TSPO gene expression [HC=healthy control].

Figure 6. Application to a rat model of LPS-induced neuroinflammation

Panel A shows the comparison of the area under the curve of TACs in SUV of homologous ROIs in *ic-LPS* rats; a significant difference is reported for cortex, basal ganglia, corpus callosum, amygdala, septal area, ventricles and white matter. Panel B shows the comparison of regional **ptspo** between the *Vehicle* and *ip-LPS* groups.

Tables

Table 1: Demographic and acquisition information for the 5 datasets under study

	<i>Dataset 1</i>	<i>Dataset 2</i>	<i>Dataset 3</i>	<i>Dataset 4</i>	<i>Dataset 5</i>
<i>Number Scans</i>	118	46	26	57	76
<i>Tracer</i>	[¹¹ C]PBR28	[¹¹ C]PBR28	[¹¹ C]PBR28	[¹⁸ F]DPA-714	[¹¹ C]-(R)-PK11195
<i>Affiliation</i>	KCL	MGH	MGH	KCL	KCL
<i>Scanner</i>	Siemens Biograph™ TruePoint™ PET·CT scanner	dedicated brain PET scanner within the bore of a Siemens 3T Tim Trio MRI scanner	Siemens Biograph mMR whole-body PET/MR scanner	SIEMENS Biograph mMR PET/MRI	GE SIGNA PET/MR
<i>Age (m±std)</i>	38 ± 19	47 ± 13	55 ± 15	39 ± 19	37 ± 8
<i>Sex (#M, #F)</i>	84 , 34	15 , 31	12 , 14	31 , 26	26 , 50
<i>Genotype (#HAB, #MAB)</i>	87 , 31	30 , 16	13 , 13	37 , 20	/
<i>Dose (mean±std)</i>	328.10 ± 32.79	488.16 ± 54.99	519.44 ± 63.04	186.88 ± 10.00	365.53 ± 50.89
<i>Clinical populations</i>	HC, UHR, SCZ, XDB173 blocking, AD	HC, FM	HC	HC, TREM2, MCI	HC, MD

HC=healthy control; UHR=ultra-high risk of psychosis; SCZ=schizophrenia; AD=Alzheimer's disease; FM=fibromyalgia; TREM2=TREM2 p.R47H carriers; MCI=mild cognitive impairment; MD=mild depressive disorders; m=mean; std=standard deviation; HAB=high affinity binding; MAB=mixed affinity binding; M=males; F=females.